1-(4-nitro-phenyl)-cyclopentanecarbonyl chloride | 422280-34-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-nitro-phenyl)-cyclopentanecarbonyl chloride
• 英文别名: 1-(4-nitrophenyl)cyclopentane-1-carbonyl chloride
• CAS: 422280-34-0
• 化学式: C₁₂H₁₂ClNO₃
• 分子量: 253.685
• InChiKey: UNLBZNRONDIBKZ-UHFFFAOYSA-N

物化性质

• 沸点：
  368.4±35.0 °C(Predicted)
• 密度：
  1.340±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-nitro-phenyl)-cyclopentanecarbonyl chloride 在 platinum on activated charcoal 氢气 作用下， 以 甲醇 、 苯 为溶剂， 反应 4.0h， 生成 methyl 1-(p-aminophenyl)cyclopentanecarboxylate
  参考文献：
  名称：

  Muscarinic receptor binding profile of para-substituted caramiphen analogs

  摘要：

  Para-substituted analogues of the antimuscarinic agent caramiphen were synthesized and evaluated for their ability to bind to the M1 and M2 subtypes of the muscarinic receptor. The purpose of the set was to look for a possible relationship in binding affinity or receptor subtype selectivity with aromatic substituent parameters such as Hammett's-sigma or Hansch's pi-values. It is felt this could be determined initially with only four properly chosen substituents. In this approach, substituents were chosen which have an extreme value for sigma and for pi, in a positive and negative direction, in all combinations. The substituents chosen for examination were amino (-sigma, -pi); 1-pyrrolidinyl (-sigma, +pi); 1-tetrazolyl (+sigma, -pi), and iodo (+sigma, +pi). It was determined in this research that caramiphen binds with high affinity (K(i) = 1.2 nM) and is selective for the M1 over M2 muscarinic receptor subtype (26-fold). An examination of para-substitution reveals that compounds with electron-withdrawing (+sigma) substituents showed M1 selectivity, while the derivatives with electron-donating groups (-sigma) were nonselective in the binding assays. On the basis of this finding, the nitro and cyano derivatives were prepared and found to be M1 selective. The +sigma derivatives showed a decrease in M2 affinity while the p-nitro and p-iodo derivatives retained approximately equal affinity as caramiphen for the M1 site. The nitro- and iodocaramiphen derivatives were as potent (M1, K(i) = 5.52 and 2.11 nM, respectively) and showed a greater selectivity of M1 over M2 binding than the M1 prototypical agent pirenzepine (M1, K(i) = 5.21 nM).

  DOI：

  10.1021/jm00114a005
• 作为产物：
  描述：

  methyl 1-(p-nitrophenyl)cyclopentanecarboxylate 在 草酰氯 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 51.0h， 生成 1-(4-nitro-phenyl)-cyclopentanecarbonyl chloride
  参考文献：
  名称：

  钯 (II) 催化的 N-甲氧基酰胺和芳烃的 C(sp2)-H 键活化/C-N 键裂解环化

  摘要：

  开发了 Pd(II) 催化的 N-烷氧基酰胺芳烃的 C-H 键活化/C- N键裂解环化反应以合成 9,10-二氢菲酮衍生物。该反应表现出良好的官能团相容性，产率高达 92%。详细的机理研究表明，C-N键断裂的关键是形成的八元钯环中间体与羰基进行亲核加成，这为N-烷氧基酰胺定向C-H键活化提供了一种新的实用途径。

  DOI：

  10.1021/acs.orglett.2c00161

文献信息

• Substituted alkanoic acids
  申请人：——

  公开号：US20040006056A1

  公开（公告）日：2004-01-08

  The invention is directed to physiologically active compounds of general formula (I): 1 wherein:- 2 represents (i) a saturated 3 to 6 membered carbocycle, optionally substituted by one or more alkyl groups, (ii) indanyl or (iii) a saturated 4 to 6 membered heterocyclic ring; R 1 represents R 3 Z 1 -Het- or R 4 N(R 5 )—C(═O)—NH—Ar 1 —; L 1 represents an —R 6 —R 7 — linkage; R 2 represents hydrogen, halogen, lower alkyl or lower alkoxy; L 2 represents an alkylene linkage; Y is carboxy or an acid bioisostere; and their corresponding N-oxides or prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their corresponding N-oxides or prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).

  该发明涉及一般式(I)的生理活性化合物： 1 其中：- 2 表示(i)饱和的3至6成员碳环，可选地由一个或多个烷基取代，(ii)吲哚基或(iii)饱和的4至6成员杂环环； R 1 表示R 3 Z 1 -Het-或R 4 N(R 5 )—C(═O)—NH—Ar 1 —； L 1 表示一个—R 6 —R 7 —连接； R 2 表示氢、卤素、低烷基或低烷氧基； L 2 表示一个烷基连接； Y为羧基或酸生物同位素； 以及这些化合物及其相应的N-氧化物或前药，以及这些化合物及其相应的N-氧化物或前药的药学上可接受的盐和溶剂。 这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4(&agr;4&bgr;1)相互作用的能力。
• Novel (4-Phenylpiperidinyl)- and (4-Phenylpiperazinyl)alkyl-Spaced Esters of 1-Phenylcyclopentanecarboxylic Acids as Potent .sigma.-Selective Compounds
  作者：Robert L. Hudkins、Richard B. Mailman、Diane L. DeHaven-Hudkins

  DOI：10.1021/jm00039a008

  日期：1994.6

  A series of novel 4-phenylpiperidinyl and (4-phenylpiperazinyl) alkyl 1-phenylcyclopentanecarboxylates was synthesized and evaluated for affinity at sigma(1) and sigma(2) sites by inhibition of [H-3]-(+)-pentazocine (PENT) and [H-3]-1,3-di(2-tolyl)guanidine (DTG) binding in guinea pig brain. The phenylpiperidines were more potent sigma ligands than the corresponding piperazines. Structural modifications varying the optimal spatial distance between the piperidine nitrogen and ester functions led to the identification of the propyl compound 24 ([H-3]PENT K-i = 0.50 nM; [H-3]DTG K-i = 1.17 nM) and the butyl derivative 32 ([H-3]PENT K-i = 0.51 nM; [H-3]DTG K-i = 0.69 nM) as novel high-affinity sigma-selective agents. An ethylene spacer was optimum with para-substituted analogs. A notable finding was the discovery of 2-(4-phenylpiperidinyl) ethyl 1-(4-nitrophenyl)cyclopentanecarboxylate hydrochloride (15) (RLH-033), which demonstrated potent affinity for the [H-3]PENT-defined sigma site with a K-i of 50 pM, selectivity for sigma(1) over muscarinic M(1) (> 17600-fold), M(2) (> 34200-fold), dopamine D-1 (> 58000-fold), and D-2 (> 7000-fold) receptors, and inactivity at phencyclidine, NMDA, and opioid receptors. RLH-033 is a valuable tool which will aid further in understanding the biology of the sigma recognition site. Information from this research has further defined the topography of the sigma recognition site, which may provide an explanation for the diverse structures which bind with relatively high affinity.
• SUBSTITUTED ALKANOIC ACIDS
  申请人：Aventis Pharma Limited

  公开号：EP1330432A2

  公开（公告）日：2003-07-30
• US7166616B2
  申请人：——

  公开号：US7166616B2

  公开（公告）日：2007-01-23
• [EN] SUBSTITUTED ALKANOIC ACIDS<br/>[FR] ACIDES ALCANOIQIES SUBSTITUES
  申请人：AVENTIS PHARMA LTD

  公开号：WO2002036553A2

  公开（公告）日：2002-05-10

  The invention is directed to physiologically active compounds of general formula (1): wherein:- A1 represents (i) a saturated 3 to 6 membered carbocycle, optionally substituted by one or more alkyl groups, (ii) indanyl or (iii) a saturated 4 to 6 membered heterocyclic ring; R1 represents R3 Z1-Het-or R4N(R5)-C(=0)-NH-Ar1-; L1 represents an R6-R7-linkage; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; L2 represents an alkylene linkage; Y is carboxy or an acid bioisostere; and their corresponding N-oxides or prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their corresponding N-oxides or prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).